Literature DB >> 8011967

Bioavailability and reversible metabolism of prednisone and prednisolone in man.

V Garg1, W J Jusko.   

Abstract

The pharmacokinetics of prednisone and prednisolone was examined in 12 healthy male subjects to assess the bioavailability and the parameters of reversible metabolism between the two steroids. After an oral prednisone dose of 0.8 mg kg-1 and an intravenous prednisolone dose of 0.66 mg kg-1, the bioavailability was found to be about 62%. The fraction of the dose recovered in the urine as the hydroxylated metabolites of prednisone and prednisolone was lower after the oral prednisone dose, suggesting that poor absorption of prednisone was the main cause of the low bioavailability. There was a high degree of interconversion between prednisone and prednisolone with 76% of the dose being recycled. The formation clearance of prednisolone from prednisone is much greater than the formation clearance of prednisone from prednisolone or the irreversible elimination clearances of the two steroids. The possible dose dependences of bioavailability and interconversion may be important factors in prednisolone therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8011967     DOI: 10.1002/bdd.2510150208

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  13 in total

Review 1.  Interventions for bullous pemphigoid.

Authors:  Gudula Kirtschig; Philippa Middleton; Cathy Bennett; Dedee F Murrell; Fenella Wojnarowska; Nonhlanhla P Khumalo
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus.

Authors:  Ileana A Ionita; Ken Ogasawara; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Ther Drug Monit       Date:  2014-08       Impact factor: 3.681

3.  Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.

Authors:  Panteleimon D Mavroudis; John van den Anker; Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; Kanneboyina Nagaraju; Paula R Clemens; William J Jusko
Journal:  J Clin Pharmacol       Date:  2019-02-11       Impact factor: 3.126

4.  Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats.

Authors:  G M Ferron; N A Pyszczynski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

Review 5.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 6.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 7.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

8.  Duration of suppression of adrenal steroids after glucocorticoid administration.

Authors:  John S Fuqua; Deborah Rotenstein; Peter A Lee
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-31

9.  Randomized clinical trial comparing oral prednisone (50 mg) with placebo before laparoscopic cholecystectomy.

Authors:  Thue Bisgaard; Svend Schulze; Niels Christian Hjortsø; Jacob Rosenberg; Viggo Bjerregaard Kristiansen
Journal:  Surg Endosc       Date:  2007-12-20       Impact factor: 4.584

Review 10.  Demographics, assessment and management of pain in the elderly.

Authors:  Mellar P Davis; Manish Srivastava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.